Quest Diagnostics Incorporated’s Stock Price Soars to $139.50, Marking a Positive 3.90% Leap in Performance

Quest Diagnostics Incorporated (DGX)

139.50 USD +5.24 (+3.90%) Volume: 2.79M

Quest Diagnostics Incorporated’s stock price is currently performing strong at 139.50 USD, witnessing a positive surge of +3.90% in this trading session with a robust trading volume of 2.79M. The stock continues to display a promising year-to-date percentage change of +1.17%, indicating a favourable investment opportunity in the healthcare sector.

Latest developments on Quest Diagnostics Incorporated

Following the FDA’s decision to regulate some tests due to concerns over reliability, Quest Diagnostics stock price experienced notable movement. The healthcare company’s stock price was further influenced by the announcement of the Quest Diagnostics Foundation’s expanded collaboration with Green Bronx Machine, a move designed to advance health equity. These key developments offer insight into the recent financial trends at Quest Diagnostics.

Quest Diagnostics Incorporated on Smartkarma

Analysts at Baptista Research have published a bullish research report on Quest Diagnostics, highlighting the company’s continued investment in new technologies and automated solutions as major drivers for growth. The report delves into Quest Diagnostics Incorporated’s fourth quarter and full year 2023 earnings call, where the company emphasized its strategy to focus on top-line growth across core customer channels and increase profitability. In 2023, Quest Diagnostics achieved a 7% revenue growth in its base business and met its earnings commitments by shifting away from COVID-19 testing. Baptista Research aims to evaluate various factors that could impact the company’s stock price in the near future and conducts an independent valuation using a Discounted Cash Flow (DCF) methodology.

A look at Quest Diagnostics Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Quest Diagnostics, a company that provides diagnostic testing and services, has received a strong overall outlook based on Smartkarma Smart Scores. With high scores in Dividend and Value, the company is seen as a stable investment with good returns for shareholders. However, its lower scores in Growth and Resilience suggest some challenges in terms of future expansion and ability to withstand economic downturns. Despite this, Quest Diagnostics shows promising Momentum, indicating positive market sentiment and potential for growth in the near future.

Quest Diagnostics operates a national network of laboratories and patient service centers, offering a range of testing services. With a focus on providing essential medical testing and information, the company plays a crucial role in the healthcare industry. While facing some hurdles in terms of growth and resilience, Quest Diagnostics‘ strong Dividend and Value scores reflect its stability and potential for long-term profitability. Investors may find the company’s overall outlook favorable, especially considering its positive Momentum score indicating growing interest in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma